BlueShore Financial Expands Relationship with Temenos to Further its Digital Transformation
13.4.2021 10:00:00 EEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that BlueShore Financial, a boutique full service financial institution, is digitally transforming with Temenos. Powered by Temenos Infinity, the market-leading omnichannel digital banking product, BlueShore will extend its ‘HighTech-HighTouch’ experience to clients by leveraging explainable artificial intelligence (XAI). BlueShore will replicate the in-branch experience of its Financial Spa™ Branch designed around client-centered amenities, personalized service and expert advice, across all channels and devices, from onboarding to servicing through to retention.
BlueShore clients are largely technologically and financially literate, but are time-starved and have complex financial needs. As such, BlueShore is focused on delivering expert advice and a premium, personalized client experience, both in-person and virtually, via the channel of their clients’ choice. In November 2020, as part of its initiative to build human connections in the digital era, and deliver a technology experience that fits its clients’ lifestyle, BlueShore signed a contract for Temenos Infinity Engage, a state-of-the-art mobile messaging app that connects BlueShore Solution Centre and Financial Advisors with clients. The expansion of the relationship to include the full Temenos Infinity digital platform, Temenos Data Lake, Temenos Explainable AI (XAI) and Temenos Payments will take this further, as BlueShore executes a data-driven, cutting-edge digital strategy.
BlueShore has been a long-standing Temenos partner, using Temenos Transact to create a high-performing cost-efficient core banking environment. Leveraging Temenos Analytics, embedded into the core banking platform, BlueShore created what it calls ‘bluegorithms’, proprietary algorithms that measure qualities such as engagement score, digital usage and price sensitivity. With the new end-to-end, fully integrated digital ecosystem, BlueShore will benefit from:
- Reduced complexity.
- An enhanced 360-degree customer view.
- The ability to leverage both blended client data from standard structured data (such as form entries) to unstructured data (such as social media and voice).
- Real-time analytics to gain valuable insights into customer behavior and preferences, fed into Temenos XAI to automatically deliver hyper-personalized experiences with tailored recommendations and contextualized advice.
- An API-first, open platform that can enrich BlueShore’s data with third-party sources, proactively facilitating open banking ahead of new regulations emerging in Canada. BlueShore will have access to over 100 of the latest Open Banking APIs being deployed globally.
- Next-generation payments technology that supports ISO20022 standards and real-time payments, enabling BlueShore to take further advantage of Canadian Payments Modernization.
Chris Catliff, President and CEO, BlueShore Financial, said: “We are delighted to start this exciting next phase of our digital transformation journey with Temenos. For over a decade, Temenos has been a strong partner of ours in our commitment to improving our clients’ financial well-being. With this expansion of the relationship, we will be able to take the Financial Spa™ experience that BlueShore is known for in-person – encouraging engaging conversations and genuine value – and deliver that in the digital realm. With Temenos, we can pursue new and untapped market opportunities with differentiated products and services that will put us at the forefront of Open Banking and Payments Modernization opportunities. We look forward to continuing to innovate with Temenos.”
Jacqueline White, President, Americas, Temenos, said: “Financial institutions recognize the value of their data as they seek to personalize customer engagement, but they don’t necessarily understand how to leverage it. BlueShore has been a pioneer for many years in leveraging data to take a highly targeted, personalized approach and deliver a premium experience. With the end-to-end Temenos platform, encompassing modernized payments and explainable AI, BlueShore will create differentiated experiences for its clients, empowering them with tailored recommendations and contextualized advice.”
– Ends –
About BlueShore Financial
BlueShore Financial is a boutique financial institution providing a full range of personal and business banking, wealth management, insurance and commercial lending solutions. With a branch network located across the Lower Mainland and Sea-to-Sky Corridor, BlueShore Financial helps clients achieve financial wellness® through personalized solutions and expert advice, delivered in a unique Financial Spa® branch environment. BlueShore Financial manages over $6.5 billion in Assets Under Administration and is consistently ranked among the top 20 financial planning firms in Metro Vancouver.
BlueShore Financial is an Imagine Canada Caring Company, contributing at least 1% of pre-tax profits annually to charities and not-for-profit organizations within the communities it serves. BlueShore Financial is the operating name of BlueShore Financial Credit Union.
Follow and connect with us on Facebook, Instagram, LinkedIn or Twitter.
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005104/en/
Contact information
Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
